Chinese Scientists Identify Key Ebola Virus Mutation That Boosted Infectivity

Chinese researchers have identified a critical mutation in the Ebola virus that significantly increased its ability to spread during one of the deadliest outbreaks in recent history, offering fresh insights that could strengthen epidemic surveillance and drug development.

The findings, published in the scientific journal Cell, come from a collaborative study led by Professor Qian Jun of Sun Yat-sen University, along with teams from Guangzhou Eighth People’s Hospital of Guangzhou Medical University, the First Hospital of Jilin University, and other Sun Yat-sen University research groups.

What the study found

The research focused on the 2018–2020 Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo (DRC), the second-largest Ebola outbreak on record. That epidemic infected more than 3,000 people and caused over 2,000 deaths.

Scientists analysed 480 complete Ebola virus genomes from the outbreak and discovered that a specific mutation in the virus’s glycoprotein — known as GP-V75A — emerged early in the epidemic. This mutated strain rapidly replaced the original virus variant as the outbreak progressed.

According to the researchers, the rise of the GP-V75A mutation closely tracked the surge in Ebola cases, strongly suggesting that the mutation gave the virus a transmission advantage.

Why this mutation matters

Laboratory experiments confirmed the biological impact of the mutation. The GP-V75A variant showed a significantly enhanced ability to infect multiple types of host cells and laboratory mice, compared with earlier strains.

The findings help answer a long-standing question about the DRC outbreak: whether factors beyond fragile healthcare systems — such as viral evolution itself — played a role in prolonging and intensifying the epidemic.

“We have long known that key viral mutations can act as invisible drivers that accelerate transmission during major outbreaks,” Professor Qian said. “This study shows that Ebola was no exception.”

Implications for treatment and vaccines

The study also raised concerns about treatment effectiveness. Researchers found that the GP-V75A mutation reduced the antiviral activity of some existing therapeutic antibodies and small-molecule drugs that block viral entry into cells.

This suggests that viral evolution during outbreaks could undermine medical countermeasures, increasing the risk of drug resistance if treatments are not continuously evaluated against emerging variants.

Importance of real-time surveillance

Experts say the findings underline the need for real-time genomic surveillance during outbreaks of emerging infectious diseases.

“This kind of monitoring not only helps warn us about changes in transmission risk,” Qian explained, “but also allows us to assess whether current drugs and vaccines will remain effective, so control strategies can be adjusted early.”